CA2825163C - Compositions for regulating iron homeostasis and methods of using same - Google Patents

Compositions for regulating iron homeostasis and methods of using same Download PDF

Info

Publication number
CA2825163C
CA2825163C CA2825163A CA2825163A CA2825163C CA 2825163 C CA2825163 C CA 2825163C CA 2825163 A CA2825163 A CA 2825163A CA 2825163 A CA2825163 A CA 2825163A CA 2825163 C CA2825163 C CA 2825163C
Authority
CA
Canada
Prior art keywords
fusion protein
pro
ser
val
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2825163A
Other languages
English (en)
French (fr)
Other versions
CA2825163A1 (en
Inventor
Patrick Gearing
Tracey Menhall
Herbert Y. Lin
Jodie L. Babitt
Original Assignee
FERRUMAX PHARMACEUTICALS Inc
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FERRUMAX PHARMACEUTICALS Inc, General Hospital Corp filed Critical FERRUMAX PHARMACEUTICALS Inc
Publication of CA2825163A1 publication Critical patent/CA2825163A1/en
Application granted granted Critical
Publication of CA2825163C publication Critical patent/CA2825163C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Obesity (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
CA2825163A 2011-01-19 2012-01-19 Compositions for regulating iron homeostasis and methods of using same Expired - Fee Related CA2825163C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161434405P 2011-01-19 2011-01-19
US61/434,405 2011-01-19
PCT/US2012/021829 WO2012150973A1 (en) 2011-01-19 2012-01-19 Compositions for regulating iron homeostasis and methods of using same

Publications (2)

Publication Number Publication Date
CA2825163A1 CA2825163A1 (en) 2012-11-08
CA2825163C true CA2825163C (en) 2019-12-03

Family

ID=47107987

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2825163A Expired - Fee Related CA2825163C (en) 2011-01-19 2012-01-19 Compositions for regulating iron homeostasis and methods of using same

Country Status (8)

Country Link
US (2) US9708379B2 (enExample)
EP (1) EP2665752B1 (enExample)
JP (2) JP2014506452A (enExample)
KR (1) KR102035357B1 (enExample)
CN (2) CN103649126B (enExample)
AU (3) AU2012251919B2 (enExample)
CA (1) CA2825163C (enExample)
WO (1) WO2012150973A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110070242A1 (en) * 2009-09-01 2011-03-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for Diagnosing and Treating Iron Dysregulation
CN104136462B (zh) * 2011-12-14 2017-06-09 艾伯维德国有限责任两合公司 用于诊断和治疗铁相关病症的组合物和方法
MX357708B (es) 2011-12-14 2018-07-20 Abbvie Deutschland Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
WO2017123642A1 (en) * 2016-01-12 2017-07-20 The Trustees Of The University Of Pennsylvania Methods and uses of osteoclast associated receptor (oscar) for prevention and treatment of osteoarthritis
WO2017216724A1 (en) 2016-06-15 2017-12-21 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
WO2019136043A1 (en) * 2018-01-03 2019-07-11 Acceleron Pharma Inc. Single-arm co-receptor fusion proteins and uses thereof
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
US20230061804A1 (en) * 2020-01-23 2023-03-02 The Rockefeller University Phase separation sensors and uses thereof
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
WO2022271716A2 (en) * 2021-06-21 2022-12-29 Keros Therapeutics, Inc. Methods of using activin receptor type ii signaling inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7459540B1 (en) * 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
EP1618131A2 (en) * 2003-04-15 2006-01-25 Xenon Pharmaceuticals Inc. Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
EP2954903A1 (en) * 2005-02-16 2015-12-16 The General Hospital Corporation Use of bmp antagonists to regulate hepcidin-mediated iron metabolism
CA2549477A1 (en) * 2005-06-29 2006-12-29 The Regents Of The University Of California Competitive regulation of hepcidin mrna by soluble and cell-associated hemojuvelin
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
US7528111B2 (en) * 2006-05-12 2009-05-05 Bristol-Myers Squibb Company Method of vaccinating subjects receiving immune modulating therapy
EP1862555A1 (en) 2006-05-29 2007-12-05 Klinikum der Universität Regensburg Means and methods for diagnosing cancer or a corresponding predisposition
WO2008124768A1 (en) * 2007-04-09 2008-10-16 The General Hospital Corporation Hemojuvelin fusion proteins and uses thereof
CN101307085B (zh) * 2007-08-01 2012-06-13 香港理工大学深圳研究院 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用
EP2033971A1 (de) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
EP2235054A1 (en) * 2007-12-13 2010-10-06 Merck Serono S.A. Sarp-1 fusion proteins and uses thereof
WO2009152944A1 (en) * 2008-05-29 2009-12-23 Hanall Pharmaceutical Co., Ltd Modified erythropoietin (epo)polypeptides that exhibit increased protease resistance and pharmaceutical compositions thereof
CA2742871C (en) * 2008-11-13 2018-10-23 Herb Lin Methods and compositions for regulating iron homeostasis by modulation of bmp-6

Also Published As

Publication number Publication date
AU2012251919A1 (en) 2013-08-15
CN107022032A (zh) 2017-08-08
JP2014506452A (ja) 2014-03-17
AU2017201782A1 (en) 2017-03-30
EP2665752A1 (en) 2013-11-27
CN103649126A (zh) 2014-03-19
AU2017201782B2 (en) 2019-01-17
WO2012150973A9 (en) 2013-01-17
AU2012251919A2 (en) 2014-06-12
JP2017025070A (ja) 2017-02-02
KR20140030134A (ko) 2014-03-11
KR102035357B1 (ko) 2019-10-23
US20180044389A1 (en) 2018-02-15
WO2012150973A1 (en) 2012-11-08
US9708379B2 (en) 2017-07-18
US10273273B2 (en) 2019-04-30
AU2019202913A1 (en) 2019-05-16
EP2665752A4 (en) 2014-09-17
US20140199302A1 (en) 2014-07-17
JP6466376B2 (ja) 2019-02-06
CA2825163A1 (en) 2012-11-08
AU2012251919B2 (en) 2016-12-15
CN103649126B (zh) 2016-11-09
EP2665752B1 (en) 2018-10-10

Similar Documents

Publication Publication Date Title
US10273273B2 (en) Compositions for regulating iron homeostasis and methods of using same
AU748369C (en) Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof,and uses thereof
US6413514B1 (en) Methods of using antibodies against human CD40
US6361946B1 (en) Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
AU711578B2 (en) Receptor ligand VEGF-C
US20040147448A1 (en) Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US20020127652A1 (en) Follicle stimulating hormones
CN101720332B (zh) 生产促卵泡激素的细胞克隆
KR20210129108A (ko) 글리코겐 저장 질환 1a형을 치료하기 위한 조성물 및 방법
WO1998033917A9 (en) Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
US20030091567A1 (en) Progenitor cell materials and methods
US9815882B2 (en) Tumor targeted Tnf-related apoptosis inducing ligand fusion polypeptide, methods and uses therefor
AU2024219754A1 (en) T cell receptors which recognize mutated EGFR
US20040038918A1 (en) Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy
CN106701806B (zh) 评估中药和/或天然药物效能的系列转录因子报告基因系统及其应用
US6379927B1 (en) Retinoblastoma fusion proteins
CN109929847B (zh) 一种pex26基因、蛋白及其应用
CN110777147A (zh) 一种ikzf3基因沉默的t细胞及其应用
KR101876486B1 (ko) Myh4 유전자를 포함하는 재조합 벡터 및 이의 이용
KR102713784B1 (ko) Tlr2 과발현 죽상동맥경화 동물 모델 및 이의 제조방법
CN1242043A (zh) 受体配体vegf-c
AU1007200A (en) Receptor ligand VEGF-C

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170116

MKLA Lapsed

Effective date: 20210119